Latest news with #MichaelHowe
Business Wire
3 days ago
- Business
- Business Wire
Guidewire Congratulates Winners of DEVHack 2025 Virtual Hackathon
SAN MATEO, Calif.--(BUSINESS WIRE)--Guidewire (NYSE: GWRE) congratulates the winners of DEVHack 2025, its second annual virtual hackathon created to engage the largest network of developers in the global P&C industry and showcase their excellence in solving real-world business challenges. The event was exclusively sponsored by Guidewire PartnerConnect Technology Alliance partner and preferred cloud provider Amazon Web Services (AWS). The 2025 winners are: First Place – Team 'GigGuards' from PwC for its AI-powered affordable insurance solution for gig workers Second Place – Team 'Green Guardians' from EY for its ESGverse solution that integrates Environmental, Social and Governance (ESG) scoring into commercial property underwriting Third Place – Team 'Change Makers' from Hexaware for its HEXperience mobility insurance solution "Congratulations to the DEVHack winners, and a sincere thank you to everyone who participated," said Guidewire Chief Product Officer Michael Howe. "Events like this hackathon and the Guidewire DEVSummits highlight the strength and innovation our global developer community brings in service to the P&C insurance industry. It has been inspiring to see such high-quality work, creative solutions, and genuine passion from developers. Also, I'd like to thank AWS for their support and partnership that made it possible for developers to push boundaries and showcase technical excellence in Guidewire Cloud." Out of nearly 200 team applications submitted from around the world, 40 teams were selected to compete in the hackathon. From June 2 - July 8, 2025, the teams worked to build solutions, leveraging a developer environment provisioned with Guidewire InsuranceSuite utilizing the Mammoth release of Guidewire Cloud Platform. The top 10 submissions were announced as finalists on July 22, 2025 and shared for public voting. Their demo videos are available to view on the DEVHack website. The three winners were celebrated at a winners announcement webinar on July 24, determined using a combination of judges' scores, 11,921 tallied public votes, and earned bonus points. To view the demo videos from all finalists and learn about the award-winning projects, visit the DEVHack website. The first-place team, PWC's GigGuards, will have the opportunity to showcase their winning solution in the demo theater during Guidewire Connections in Las Vegas, October 27-30, 2025. Stay informed about the Guidewire Developer program through the Developer Newsletter. About Guidewire Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurers in 42 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers. We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest solution partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation. For more information, please visit and follow us on X (formerly known as Twitter) and LinkedIn. NOTE: For information about Guidewire trademarks, visit .
Business Wire
6 days ago
- Business
- Business Wire
Guidewire Niseko Release Delivers Financial and Risk Insights, Bringing Unprecedented Clarity Into Business Performance
SAN MATEO, Calif.--(BUSINESS WIRE)--Guidewire (NYSE: GWRE) announces Niseko, its latest release, designed to give insurers unprecedented insight into financial performance and risk exposure. Niseko empowers developers with tools that streamline updates to custom software extensions, automate and reuse core business functions to speed development, and enhance operational efficiency through intelligent automation. 'With Niseko, developers now have access to pre-built insurance data models that enhance access to complex core data and come with built-in financial and operational intelligence for improved decision-making,' said Diego Devalle, Chief Product Development Officer, Guidewire. 'Niseko also introduces a dedicated extension layer that simplifies software customization, and Guidewire Functions that automate business tasks and logic to enhance the development process.' Niseko delivers new offerings and functionality designed to help insurers: Gain faster financial and business insights with Policy Insurance Data Model and Claims Insurance Data Model. These are auto-generated, dimensional models that simplify access to underlying InsuranceSuite policy and claims data. Modernize the development process and accelerate business logic implementation with Guidewire Functions. Enabled using a Functions-as-a-Service approach, developers can quickly build modular, reusable business tasks and logic to improve software quality while delivering more reliable and adaptable business solutions.* Customize with confidence with the new Extension Layer that provides an update-safe architectural layer for all custom extensions to Guidewire applications.** Understand wildfire risk faster and with greater precision with HazardHub Wildfire Risk Score 3.0, the latest and most accurate wildfire risk assessment tool from Guidewire. Trained on millions of records and back-tested against real-world claims, the model is proven highly predictive of unforeseen wildfire events. Automate the creation and management of activity assignments within PolicyCenter, ensuring that tasks are assigned to the right underwriters based on predefined rules with the Autopilot Activity Handling Integration. Assess risk and ensure stability while staying competitive and compliant by analyzing premiums (written, inforce, earned, unearned) over time and across lines of business with Premium Analysis Business Intelligence (BI) Content. Maintain a healthy financial position, implement loss control strategies, and reveal emerging trends in claim patterns by analyzing losses (paid, incurred, reserves, recovery, and loss adjustment expense) historically and spanning business products with Loss Analysis BI Content. 'Every Guidewire release is designed to remove complexity and deliver meaningful value for our customers,' said Michael Howe, Chief Product Officer, Guidewire. 'Niseko is a reflection of that commitment, equipping insurers with the clarity, speed, and agility they need to thrive in a fast-changing P&C insurance industry.' For more detailed information, please visit our website and read the Niseko overview blog. Certain release features may not be available in all regions. *Indicates product feature is available to a limited number of customers only. ** Indicates product feature is available for Early Access customers only. About Guidewire Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurers in 42 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers. We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest solution partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation. For more information, please visit and follow us on X (formerly known as Twitter) and LinkedIn. NOTE: For information about Guidewire trademarks, visit Cautionary Language Concerning Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the general availability of features, programs, services, and tools related to Niseko mentioned in this press release (including, without limitation, Policy Insurance Data Model, Claims Insurance Data Model, Guidewire Functions, and HazardHub Wildfire Risk Score 3.0). These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as 'expect,' 'anticipate,' 'should,' 'believe,' 'hope,' 'target,' 'project,' 'goals,' 'estimate,' 'potential,' 'predict,' 'may,' 'will,' 'might,' 'could,' 'intend,' variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Guidewire's control. Guidewire's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in Guidewire's most recent Forms 10-K and 10-Q filed with the Securities and Exchange Commission as well as other documents that may be filed by Guidewire from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: quarterly and annual operating results may fluctuate more than expected; seasonal and other variations related to our customer agreements and related revenue recognition may cause significant fluctuations in our results of operations, Annual Recurring Revenue ('ARR'), and cash flows; our reliance on sales to and renewals from a relatively small number of large customers for a substantial portion of our revenue and ARR; our making long-term pricing commitments in our customer contracts based on available information and estimates about our future costs that may change; our ability to successfully manage our business model, including achieving market acceptance of our cloud-based services and products and the costs related to cloud operations, cybersecurity, product development, and services; the timing, success, and number of professional services engagements and the billing rates and utilization of our professional services employees and contractors; the impact of global events (including, without limitation, ongoing global conflicts, inflation, high interest rates, economic volatility, bank failures and associated financial instability, and supply chain issues) on our employees, our business, and the businesses of our customers, system integrator ('SI') partners, and vendors; data security breaches of our cloud-based services and products or unauthorized access to our employees' or our customers' data; our competitive environment and changes thereto; issues in the development and use of artificial intelligence and machine learning combined with an uncertain regulatory environment; use of AI by our workforce may present risks to our business; errors or failures in our products or services, as well as service interruptions or failure of the third-party service providers we rely on; our services revenue produces lower gross margins than our license, subscription and support revenue; our product development and sales cycles are lengthy and may be affected by factors outside of our control; the impact of new regulations and laws (including, without limitation, security, privacy, artificial intelligence and machine learning, tax regulations and laws, and accounting standards); assertions by third parties that we violate their intellectual property rights; weakened global economic conditions may adversely affect the P&C insurance industry, including the rate of information technology spending; our ability to sell our services and products is highly dependent on the quality of our professional services and SI partners; the risk of losing key employees; the challenges of international operations, including changes in foreign exchange rates; and other risks and uncertainties. Past performance is not indicative of future results. The forward-looking statements included in this press release represent Guidewire's views as of the date of this press release. Guidewire anticipates that subsequent events and developments will cause its views to change. Guidewire undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Guidewire's views as of any date subsequent to the date of this press release.
Miami Herald
24-06-2025
- Business
- Miami Herald
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the last patient was dosed in its Phase 1 single-center clinical study of its oral transmucosal fast-acting high-dose aspirin formulation. Topline results from the study are anticipated by the middle of third quarter of 2025. "The successful completion of patient dosing in our Phase 1 trial is a noteworthy accomplishment. We are extremely grateful to the investigator and patients who participated in this study. Achieving this milestone on time and as planned per protocol also demonstrates the operational excellence of our team and clinical partners," said Michael Howe, Chief Executive Officer of Aspire. "We look forward to reporting initial safety and efficacy data in the third quarter, which will provide key insights into our formulation of high-dose aspirin and its potential as a fast-acting treatment option for suspected acute myocardial infarction. Following the receipt of the topline results, we plan to continue discussions with the FDA to ensure our path forward is well-aligned with regulatory expectations." Howe added, "We are eager to integrate the insights from this trial into our comprehensive development plan. We believe these trial results will also play a key role in our strategy to pursue potential partnership opportunities." Phase 1 Study Design The Phase 1 clinical trial, which is being conducted in the United States, compares the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers after the administration of our sublingual dose of 162.5 mg aspirin powder with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours post-dose). The trial also measures Arachidonic acid (AA)-induced platelet aggregation over 8 hours after dosing and Serum thromboxane B2 (TxB2) over 8 hours after dosing, both of which are valuable for documenting Aspire's sublingual high-dose aspirin's rapid impact on cardiac events. Following completion of this trial, Aspire plans to submit a section 505(b)(2) NDA seeking approval to market the high-dose aspirin product. About the Aspire Targeted Oral Delivery Platform Aspire's technology delivers a soluble, fast-acting granular or powder formulation which has been developed by using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of drugs and other substances. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities. About Aspire Biopharma, Inc. Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit Safe Harbor Statement Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Aspire Biopharma Holdings, Inc. Contact TraDigital IRKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma Holdings, Inc.
Miami Herald
10-06-2025
- Business
- Miami Herald
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025 Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby's, and as an early-stage investor/board member in healthcare and software businesses HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors has elected Michael C. Howe, as the Company's new chief executive officer. The Board selected Michael Howe to be CEO based on his proven track record of hands-on success during his more than four decades of experience with leading brands and early-stage companies, and his recognized leadership qualities. Kraig Higginson, who has stepped down as CEO and Chairman of the Board, will remain with the Company and serve as Executive Chairman of the Board. Michael Howe is a visionary C-level executive with a proven record of driving transformative success across diverse industries. With a deep understanding of market trends, consumer behavior, and innovative brand positioning, Howe has consistently demonstrated his ability to foresee and shape consumer trends, leading to the creation of groundbreaking operational strategies. His career has been marked by his ability to build and strengthen nationally recognized brands with companies such as MinuteClinic, Procter & Gamble, PepsiCo and Arby's. His strategic leadership has consistently delivered significant growth and financial success, from start-ups to multinational corporations. His healthcare leadership and expertise in creating innovative consumer focused brands was most effectively demonstrated in his leadership of MinuteClinic, a network of board-certified health providers offering high-quality, team-based care services. Howe joined MinuteClinic in June 2005 with 19 clinics in two markets as the brand struggled to define a clear national expansion strategy. Within 15 months, Howe added more than 100 clinics in 13 markets and facilitated the sale of the company to CVS in September 2006, which delivered a nearly sixfold return for investors. He stayed with CVS as CEO of MinuteClinic for 2 additional years leading the national expansion to more than 530 clinics. Since 2022, Howe has served as a Co-founder and CEO of The Good Clinic (TGC), which offered a holistic care approach to primary healthcare services, integrating functional medicine, genetic testing, technology, alternative treatments, and nutrition. Howe is now leading the funding and expansion to relaunch the TGC concept under the newly formed First Choice Healthcare Solutions. Since 2021, he has also served as an independent director for P1 Dental Partners, an Indianapolis-based, PE-funded dental services organization. "Michael is a seasoned strategist with a track record of driving sustainable growth through innovation, and we have every confidence in his ability to lead Aspire during this important time," said Kraig Higginson, Executive Chairman of Aspire. "He brings meaningful expertise in scaling differentiated platforms and has a deep understanding of the health and wellness sector - making him uniquely suited to serve as Aspire's next CEO. I have worked closely with Michael over the past six months as a fellow board member during which time his contributions and insights have confirmed the excellent qualities he brings to the role. Together with the entire Board, I look forward to working with him." On his appointment, Howe said, "I am honored to be named as CEO of Aspire. I am grateful to our Executive Chairman, Kraig Higginson for his commitment, leadership and passion, and to the members of our Board for their leadership, particularly in these recent months, and for the confidence they have placed in me to lead our business." Howe continued "Aspire has a powerful and differentiated drug delivery platform, is engaged in an important clinical trial which could support a submission to the FDA via the 505(b)(2) pathway, and has the opportunity to generate early revenue upon the launch of its novel pre-workout supplement, both of which are expected to occur in 2025. I am eager to build upon the work the entire Aspire team has been doing to position our business for the future and create value for our shareholders over the long-term." Higginson added, "It has been a privilege to lead Aspire. I am proud of what we have accomplished, and I want to express my thanks to the many team members who, through their hard work and commitment to the company, have made our success possible. From the going public process, to commencing the first FDA clinical trials of our high-dose aspirin, to preparing for the launch of our innovative pre-workout product, BUZZ BOMB™, now is the right time to transition the leadership of Aspire to Michael. I believe the Company and shareholders will benefit from his experience as a strategic thinker with a laser focus on capturing current market and operational opportunities." About Michael C. Howe A successful growth-oriented CEO with 40+ years of consumer and healthcare experience. Howe has established a proven track record of leading and building successful consumer focused businesses across several different business sectors including consumer goods, fast food restaurants, SaaS products, and innovative healthcare companies. He began his career at Procter & Gamble with positions in sales and marketing. He then joined PepsiCo in their fast-food division with operational roles with the KFC brand. Five years later, he joined Arby's as a senior operational executive, subsequently rising to the position of President and CEO, growing the brand's revenue by 25% in just 3 years. After a successful term as CEO of Arby's, Howe joined MinuteClinic in June 2005 and within 15 months orchestrated the sale of the company to CVS in September 2006, where he remained for 2 additional years leading the national expansion. After leaving CVS in 2008, he founded Howe & Associates, which focused on supporting start up and early- stage companies in their expansion processes, as an angel investor, board member, and / or executive, leading 11 companies to a successful financial exit. Howe earned both his accounting and business degrees from the University of Minnesota, Duluth after serving 4 years in the U.S. Air Force. About the Aspire Targeted Oral Delivery Platform Aspire's sublingual delivery technology has been developed using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of supplements and other substances. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities. About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which can deliver supplements and drugs rapidly and precisely. For more information, please visit Safe Harbor Statement Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Aspire Biopharma Holdings, Inc. ContactTraDigital IRKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma Holdings, Inc.
Yahoo
19-02-2025
- Business
- Yahoo
Bill increasing financial reporting for public officials advances in North Dakota House
North Dakota Secretary of State Michael Howe speaks during a legislative committee hearing on Jan. 23, 2025. (Mary Steurer/North Dakota Monitor) The House on Tuesday night voted 64-26 to require public officials to file statements of interest annually. Current law only requires officials to submit one statement of interest form when they file for candidacy or when they're appointed to office. Statewide officials file their forms with the Secretary of State's Office, while local government officials file with their respective local offices. The primary sponsor of House Bill 1469, Rep. Glenn Bosch, R-Bismarck, said the proposal will increase public transparency as well as make the submission process more straightforward for officials. 'Hopefully we can see that helps provide clarity for us, too, when we have to fill this out,' he said on the House floor. More financial reporting proposed for North Dakota elected officials The proposal is supported by the North Dakota Ethics Commission and the Secretary of State's Office. House Majority Leader Rep. Mike Lefor and Senate Majority Leader Sen. David Hogue are also sponsoring the bill. The bill adds the following reporting requirements: A list of any local governments or state agencies that the individual or their spouse have provided more than $5,000 worth of goods or services to. A list of any employer, business or trust in which the individual or their spouse has more than a 10% stake in. Currently, candidates or appointees must only report the following information: The employer and principal source of income of that individual and their spouse. The name of any businesses or trusts in which the individual and their spouse have a financial interest. A list of associations with which the individual or spouse 'are closely associated' or of which either is an officer or director. Business offices, directorships or fiduciary relationships held by the individual and their spouse within the past year. The proposal would also require the Secretary of State's Office to publish the forms filed with its office online. The forms are not online now and there can be a fee to obtain them. North Dakota's likely next governor would regulate his own industry, testing ethics guardrails Rep. Dan Ruby, R-Minot, said the proposal would be tedious for him, since his business serves dozens of local governments across the state. Ruby's legislative bio says he owns a sanitation and landfill business. 'I'd probably have over 60 towns and counties,' Ruby, who voted against the bill, said on the floor. 'Do they really want a list of every customer that we have that might be a municipality? That just seems kind of unnecessary.' Bosch acknowledged that the bill would require more work from people like Ruby, but that complying with the new requirements would be easy for most officials, especially after the first year. 'For me, I think those two measurements – if you own more than 10% of a business, if you do more than $5,000 worth of business with that political sub — are thresholds that we can all live with,' Bosch said. The bill advances to the Senate for further consideration. In 2017, lawmakers considered a bill that would have made statements of interest available online to the public for free. The bill got amended to a study and the proposed changes were not implemented. SUPPORT: YOU MAKE OUR WORK POSSIBLE SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
